NCT07105319 (ROPEG) is a Phase 4 clinical trial of Ropeginterferon in CML (Chronic Myelogenous Leukemia), sponsored by Dong-Wook Kim.

Who is sponsoring NCT07105319?

NCT07105319 is sponsored by Dong-Wook Kim.

What drugs are being tested in NCT07105319?

Interventions in NCT07105319: Ropeginterferon.

What condition does NCT07105319 study?

NCT07105319 studies CML (Chronic Myelogenous Leukemia).

Is NCT07105319 still recruiting?

NCT07105319 is currently completed. Last updated 22 August 2025.

Last reviewed 2025-08-22 · How we verify

NCT07105319: ROPEG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropeginterferon for Treatment Free Remission

Completed Phase 4 Last updated 22 August 2025

What this trial tests

Phase 4 trial testing Ropeginterferon in CML (Chronic Myelogenous Leukemia) in 65 participants. Completed in 30 July 2025.

Timeline

30 November 2021

Primary endpoint
30 July 2025

30 July 2025

Quick facts

Lead sponsor	Dong-Wook Kim
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	65
Start date	30 November 2021
Primary completion	30 July 2025
Estimated completion	30 July 2025
Sites	1 location across South Korea

Drugs / interventions tested

Ropeginterferon — full drug profile →

Conditions studied

CML (Chronic Myelogenous Leukemia) — all drugs for CML (Chronic Myelogenous Leukemia) →

Sponsor

Dong-Wook Kim

Who can join

Adults 19 to 75, any sex, with CML (Chronic Myelogenous Leukemia). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability. In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 μg at week 0, 350 μg at week 2, 500 μg at week 4, and thereafter 500 μg bi-weekly until week 24.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interferon-Based Therapeutics in Cancer Therapy: Past, Present, and Future.
Vorona K, Ryapolova A, Sokolova O, Karabelsky A, et al · · 2025 · PMID 41373826 · DOI 10.3390/ijms262311679

Verify or expand the search:

Other trials of Ropeginterferon

Trials testing the same drug.

NCT03831776 — Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis · Phase 2 · completed

Other Dong-Wook Kim trials

Trials by the same sponsor.

NCT06945146 — Genomics Study in CML Patients With Ponatinib Treatment · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07105319 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dong-Wook Kim
Last refreshed: 22 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07105319.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing